Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulation and thrombolytic therapy. Practical considerations.

C M Kessler1

  • 1Division of Hematology-Oncology, George Washington University Medical Center, Washington, D.C.

Chest
|May 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pain in haemophilia: are we listening?

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Efficacy and safety of Nuwiq<sup>®</sup> (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Acquired haemophilia in cancer: A systematic and critical literature review.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Pinpointing clinical phenotypes - Is there evidence to support the use of a simple scoring system to define a milder bleeding phenotype in severe haemophilia A?

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same journal

The effect of a two-day stay at high altitude (2500 m) on right ventricular afterload and oxygen delivery in patients with pulmonary vascular disease A randomized controlled crossover trial.

Chest·2026
Same journal

A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy.

Chest·2026
Same journal

Independent Prognostic Contributions of Anti-Ro52 and Anti-MDA5 in Autoimmune-Associated Interstitial Lung Disease.

Chest·2026
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
Same journal

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
See all related articles

Thrombolytic agents show promise but face slow adoption due to bleeding risks. Newer agents offer improved safety and efficacy, paving the way for better thrombotic event management.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Medical Thrombosis

Background:

  • Thrombolytic agents have been available for over a decade, demonstrating efficacy in thrombotic conditions.
  • Slow acceptance is attributed to a higher incidence of hemorrhagic complications compared to anticoagulants.

Purpose of the Study:

  • To review the pharmacology of thrombolytic agents and their role in managing thrombotic phenomena.
  • To discuss the impact of second-generation agents on clinical efficacy and safety.
  • To highlight the importance of understanding coagulation for optimizing treatment and minimizing risks.

Main Methods:

  • Review of existing literature on thrombolytic agents and coagulation.
  • Analysis of clinical data regarding safety and efficacy profiles.

Related Experiment Videos

  • Discussion of advancements in recombinant DNA technology and chemical modifications.

    • Main Results:

    • Second-generation thrombolytic agents exhibit increased fibrin specificity, leading to improved clinical outcomes.
    • Despite advancements, hemorrhagic complications remain a concern, necessitating careful patient selection and monitoring.
    • Innovative regimens, including dose modifications and synergistic combinations, are expected to further enhance therapeutic benefits.

    Conclusions:

    • Understanding coagulation and the pharmacology of antithrombotics is crucial for effective treatment.
    • Advancements in thrombolytic therapy offer improved efficacy and safety for thrombotic conditions.
    • Future strategies will focus on optimizing drug regimens to maximize benefits and minimize hemorrhagic risks.